with CA and without this manifestation revealed higher frequency of splenomegaly (28 vs. 11 %, p = 0.002). The median of SLICC/ACR-DI score [1(0-9) vs. 0(0-7), p = 0.003] was significantly higher in CA patients compared to patients without this manifestation, likewise the frequency of musculoskeletal damage (31 vs. 9 % p = 0.001). Frequencies of treatment with nonsteroidal anti-inflammatory drugs (75 vs. 26 %, p < 0.0001), hydroxychloroquine sulfate (87 vs. 59 %, p = 0.001) and methotrexate (47 vs. 22 %, p = 0.001) were significantly higher in CA patients. This large multicenter study allowed us to characterize CA as a rare and early manifestation of cSLE, frequently mimicking JIA at disease onset. It is predominantly polyarticular, involving more often hands and ankles and it is associated with significant musculoskeletal accrual damage.
Introduction
Systemic lupus erythematosus (SLE) is a rare autoimmune disease more common in adults (aSLE) with only 10-20 % of cases beginning during childhood or adolescence [1] . Childhood-onset SLE (cSLE) is characterized by the involvement of various organs and systems with different disease presentations and leading to significant morbidity and mortality [2] .
Acute articular involvement is one of the most common and earliest symptoms at cSLE onset. It has been reported in 60-90 % of cSLE patients and it is typically symmetric, nonerosive and nondeforming, with polyarticular involvement, affecting both large and small joints [2, 3] .
Abstract Chronic arthritis (CA) is an unusual condition in childhood-onset systemic lupus erythematosus (cSLE) and data in children is very limited. The aim of the study is to assess CA in a large population of cSLE patients, in a multicenter cross-sectional study including 852 cSLE patients followed in ten Pediatric Rheumatology referral services in state of São Paulo, Brazil. CA was observed in 32/852 (3.7 %) cSLE patients mostly in hands and ankles. Chronic monoarthritis was diagnosed in four cSLE patients, oligoarthritis in nine and polyarthritis in 19. In the latter group, six had rhupus syndrome. Two oligoarticular patients had Jaccoud's arthropathy. CA was an isolated manifestation observed at disease onset in 13/32 (41 %) cSLE patients, and juvenile idiopathic arthritis (JIA) was the first diagnosis in 18/32 (56 %). The comparison of last visit of patients On the other hand, chronic arthritis (CA) is an unusual condition in aSLE [4, 8] and in cSLE [3, 6] . Data in children has been limited mostly to case reports [3, [5] [6] [7] and to a large single center study comparing adults and children with CA focusing solely on distinct features in these two age brackets [8] . There are, however, no data regarding the possible clinical associations of CA in cSLE patients with and without this condition.
Therefore, the objective of this study was to assess CA in a large tertiary multicenter population of cSLE patients to evaluate the possible demographic and cumulative clinical, laboratorial and treatment associations with this musculoskeletal manifestation.
Methods

Study design and patients
A multicenter cross-sectional study was performed including all the consecutive cSLE patients followed in ten Pediatric Rheumatology referral services in the state of São Paulo, Brazil. Exclusion criteria were: incomplete medical charts, undifferentiated connective tissue disorder with three or fewer American College of Rheumatology (ACR) criteria for SLE [9] , isolated cutaneous lupus erythematosus, neonatal lupus erythematosus, drug-induced lupus and other autoimmune diseases. The remaining cSLE patients fulfilled the ACR criteria for SLE [9] , with disease onset before 18 years of age [10] and current age up to 25 years old. The cohort was evaluated at the time of the diagnosis and at patients' last visit. In all the participant centers, the Committee for Research Ethics approved the study.
An investigator meeting was held for this study to define the protocol, including definitions of clinical, laboratory and treatment parameters and disease activity and damage score. All investigators used the same specific database.
All patient's medical charts were reviewed according to an extensive standardized protocol for demographic data, CA characteristics, other clinical features, laboratorial findings, therapeutic data and outcome (articular deformity, cumulative damage and death). CA was defined as the presence of swelling or effusion or two or more of the following: limitation in the range of joint movement, pain or tenderness on motion and increased temperature for at least 6 weeks [8, 11] . Arthritis features were also evaluated: duration, number and type of joints with arthritis, number and type of joints with limitation in range of motion and deformity, and radiographic changes (juxta-articular osteopenia, joint-space narrowing and erosion). Rhupus was characterized as the association of cSLE and chronic inflammatory arthritis with erosive damage with or without positive rheumatoid factor [3, 5, 6, 8 ]. Jaccoud's arthropathy was diagnosed as a nonerosive arthropathy with marked articular dislocation or subluxation leading to severe deformity of the hands and feet. [8, 12] .
Demographic data, clinical evaluation, disease activity, disease damage and drug therapy Demographic data analysis included: age at cSLE onset, disease duration, age at last visit, gender and ethnicity. Descriptors and definitions of disease activity regarding SLE clinical manifestations were based on SLE Disease Activity Index 2000 (SLEDAI-2 K) score, and were evaluated at last visit [13] . Other cumulative SLE clinical manifestations included fever (axillary temperature higher than 37.8 °C), weight loss >2 kg, lymphadenopathy (peripheral lymph node enlargement >1.0 cm), hepatomegaly [based on physical exam with liver edge ≥2 cm below the right costal margin or imaging (ultrasound or computer tomography when available)] and splenomegaly [based on physical exam with palpable spleen or imaging (ultrasound or computer tomography when available)] [14] . Neuropsychiatric lupus included 19 syndromes according to ACR classification criteria [15] . Antiphospholipid syndrome was diagnosed according to the preliminary criteria for the classification of pediatric antiphospholipid syndrome [16] . High blood pressure was defined as systolic and/or diastolic blood pressures ≥95th percentile for gender, age and height on ≥3 occasions [17] . Acute kidney injury was determined by sudden increase in serum creatinine above 2 mg/dl [18] or by modified RIFLE (Risk, Injury, Failure, Loss of kidney function and End-stage kidney disease) criteria [19] . Chronic renal disease was defined as structural or functional abnormalities of the kidney for ≥3 months (with or without decreased glomerular filtration rate) or glomerular filtration rate <60 ml/min/1.73 m 2 for ≥3 months [20] . Laboratorial assessment included retrospective analysis of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), complete blood cell count, serum urea and creatinine, urinalysis and 24-hour urine protein excretion. Complement levels (CH50, C3 and C4) were assessed by immunodiffusion, turbidimetric immunoassay or immunonephelometry. Antinuclear antibodies (ANA) were tested by indirect immunofluorescence; anti-double-stranded DNA (anti-dsDNA) by indirect immunofluorescence or enzyme linked immuno sorbent assay (ELISA); anti-Sm and anti-RNP by passive hemagglutination or ELISA; anti-SSA/Ro and anti-SSB/La by contraimmunoelectrophoresis or ELISA; anticardiolipin (aCL) IgG and IgM autoantibodies by ELISA. All the autoantibodies profiles were carried out at each center. The cutoff values from the kit manufacturer were used to define abnormal. Lupus anticoagulant was detected according to the guidelines of the International Society on Thrombosis and Hemostasis [21] . Further characterization of CA patients included rheumatoid factor determination by latex fixation test, nephelometry or ELISA and conventional radiography of the affected joints.
SLE disease activity and cumulative damage were scored through the SLEDAI-2K [13] and the Systemic Lupus International Collaborating Clinics/ACR-Damage Index (SLICC/ACR-DI) [22] , respectively.
Cumulative drug treatment data (prednisone, intravenous methylprednisolone, chloroquine diphosphate, hydroxychloroquine sulfate, methotrexate, azathioprine, cyclosporine, mycophenolate mofetil, intravenous cyclophosphamide, intravenous immunoglobulin, rituximab and plasmapheresis) were also recorded.
Patients were divided in two groups for the assessment of cSLE cumulative clinical manifestations, cumulative laboratory tests and autoantibodies evaluation and cumulative treatment at last visit: patients with CA and without CA.
Results were presented as numbers (%) for categorical variables and median (range) or mean ± SD for continuous variables. Categorical variables comparisons were assessed by Pearson χ-Square or Fisher's exact test and continuous variables comparisons by Mann-Whitney test or t test. The significance levels of the independent variable were set at 5 % (p < 0.05). Holm-Bonferroni correction for multiple comparisons was performed adjusting the significance level (p < 0.0038).
Results
The study was performed including 1017 cSLE patients followed in the participant's referral services. One hundred and sixty-five patients were excluded due to: incomplete medical charts (n = 96), undifferentiated connective tissue disorder with three or fewer ACR criteria (n = 43), isolated cutaneous lupus erythematosus (n = 11), neonatal lupus erythematosus (n = 8), drug-induced lupus (n = 5) and other autoimmune diseases (n = 2). All the remaining 852 cSLE patients fulfilled the inclusion criteria.
CA was found in 32/852 (3.7 %) cSLE patients. CA is usually an early disease manifestation with a median period between arthritis and cSLE diagnosis of 1.0 month. The arthritis lasted up to 70 months with a median duration of 4.5 months. In 13/32 (41 %) patients CA occurred as an isolated manifestation before lupus diagnosis. Juvenile idiopathic atrthritis (JIA) was the first diagnosis in 18/32 (56 %) patients. The most frequently involved joints were small joints of the hands such as proximal interphalangeal joints (25 %) and metacarpophalangeal joints (18 %) followed by ankles (16 %), knees (12 %) and wrists (11 %). Chronic monoarthritis was observed in four (13 %) cSLE patients, oligoarthritis in nine (28 %) and polyarthritis in 19 (59 %) patients. In the latter group, 6/19 (31 %) had rhupus syndrome (all of them with joint erosion and three with positive rheumatoid factor). Among the oligoarthritis group 2/9 (22 %) had concomitantly CA of knees and Jaccoud's arthropathy (involving flexion contracture and ulnar deviation of the metacarpophalangeal joints). Deformity and radiographic changes were observed in about one third of patients. Joints with limitation of range of motion were more frequent in proximal interphalangeal joint (21 %), metacarpophalangeal joint (19 %), wrists (13 %), ankles (10 %) and elbows (10 %). The features of chronic arthritis in 32/852 cSLE are shown in Table 1 .
Further comparison of demographic data and cumulative clinical manifestations in 852 cSLE patients with and without CA at the last visit are illustrated in Table 2 . After Holm-Bonferroni correction for multiple comparisons (p < 0.0038), the only statistically significant differences were the time of follow-up since the diagnosis [5.7 (0.7-14.8) vs. 4.5 (0-23.2) years, p < 0.0001] and frequency of splenomegaly (28 vs. 11 %, p = 0.002) that were both higher in cSLE patients with CA compared to those without this manifestation ( Table 2 ). The frequencies of other cumulative clinical manifestations were similar in both groups (p > 0.0038, Table 2 ).
Disease activity and cumulative damage as well as laboratory tests and autoantibodies evaluation of 852 cSLE patients are shown in Table 3 . After Holm-Bonferroni correction for multiple comparisons (p < 0.0038), the median of SLICC/ACR-DI score [1 (0-9) vs. 0 (0-7), p = 0.003] was significantly higher in CA patients compared to patients without this complication. Further analysis of organ damage by system revealed that frequency of musculoskeletal score (31 vs. 9 % p = 0.001) was higher in the former group. The frequencies of other cumulative laboratory tests and autoantibodies were similar in both groups (p > 0.0038, Table 3 ).
Frequencies of cumulative treatment in cSLE patients are presented in Table 4 . The frequency of use of hydroxychloroquine sulfate (87 vs. 59 %, p = 0.001), nonsteroidal anti-inflammatory drugs (75 vs. 26 %, p < 0.0001) and methotrexate (47 vs. 22 %, p = 0.001) were significantly higher in CA patients.
Discussion
Our multicenter study characterized CA as a rare manifestation of cSLE patients with a cumulative musculoskeletal damage. Patients had a predominance of a symmetric polyarthritis, involving mainly hands and ankles, and JIA was the first diagnosis in more than half of cSLE patients.
The great advantage of this study was the inclusion of a large multicentric population allowing a significant representation of CA in children and adolescents with cSLE, evaluating their characteristics and other possible associations. The use of a standardized database minimized any bias regarding clinical parameters and disease activity/damage score definitions. In addition, few previous reports had a clear definition of CA and rhupus in children, precluding an accurate comparison with their findings [8, 11] . The main limitations of this study were the retrospective design and possible missing data, and the use of only one radiological imaging method. All of the participant centers are tertiary Pediatric Rheumatology referral services. These are the only centers that provide treatment for rheumatic diseases in the state of São Paulo.
CA can mislead and delay the diagnosis of lupus since JIA was the first diagnosis in more than half of these patients. We hypothesize that chronic arthritis was the first cSLE manifestation and misdiagnosed as JIA. In fact, the 1982 revised ACR criteria [9] definition states that a given criteria should be present, serially or simultaneously, during any interval of observation.
Rhupus was present in 19 % of CA cases. Some studies suggest that this manifestation may distinguish a subset of patients with overlap of JIA/rheumatoid arthritis and SLE. However, there are no established definitions on whether it is an overlap condition or rhupus is in fact a spectrum of lupus musculoskeletal involvement [3-8, 11, 23] . Of note, we provide the first description of Jaccoud's arthropathy in cSLE patients characterized by a nonerosive periarticular and capsular disorder occurring as a late manifestation of disease. This condition was a very rare manifestation of cSLE with a frequency comparable to the reported in adult SLE [4, [24] [25] [26] [27] .
Importantly, SLICC/ACR-DI describes accrual damage and our cSLE patients had a significant musculoskeletal cumulative score, indicating that these patients may not have a favorable outcome due to permanent joint deformity.
In our study, the autoantibody profile did not distinguish cSLE patients with CA. In contrast, lupus arthropathy in adults was reported to be associated with specific autoantibodies profile, particularly anti-dsDNA, anti-Sm, anti-SSA/ Ro, rheumatoid factor and antiphospholipid antibodies [4, 25, 27] . As expected, treatment of CA in cSLE included nonsteroidal anti-inflammatory drugs and antimalarials in more than three-quarter of patients. The higher frequency of methotrexate use may be related to the fact that this drug was recommended for those with persistent or refractory articular manifestation [3] and the median duration of chronic arthritis observed herein was long enough to indicate this drug. In conclusion, this was the first study that characterized CA as a rare and early manifestation of cSLE, frequently mimicking JIA at disease onset. It is predominantly polyarticular, involving more often hands and ankles and it is associated with significant musculoskeletal accrual damage.
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